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Abstract
The production of antimicrobial peptides, such as the cathelicidins, plays a
prominent role in the innate immune response against microbial pathogens.
Cathelicidins are widely distributed amongst living organisms, and the
antimicrobial peptides generated by proteolysis of the precursor forms are
typically cationic and a-helical, a structure that facilitates their interaction and
insertion into anionic bacterial cell walls and membranes, causing damage and
promoting microbial death. Here, we found that mouse cathelicidin (Camp)
expression was induced in bone marrow-derived macrophages by infection with
Mycobacterium avium in a TLR2- and TNF-dependent manner. However, the
endogenous production of the cathelin-related antimicrobial peptide (CRAMP)
was not required for the bacteriostasis of M. avium either in primary cultures of
macrophages or in vivo, as shown by the use of CRAMP-null mice. In contrast, the
lack of Camp led to a transient improvement of M. avium growth control in
the spleens of infected mice while at the same time causing an exacerbation of the
inflammatory response to infection. Our data highlight the anti-inflammatory
effects of CRAMP and suggests that virulent mycobacteria may possess strategies to
escape its antimicrobial activity.
Introduction
Innate immunity provides the first line of defense against
infection by pathogenic microorganisms. An important
branch of innate immunity is composed by antimicrobial
peptides (AMPs), a group of unique and diverse molecules
with a wide range of microbicidal activity [1, 2]. Among
these AMPs, cathelicidins are found in every mammal that
has been examined, and can be expressed in circulating
neutrophils [3], epithelial cells of the skin [4], urinary
and gastrointestinal tracts [5, 6], blood-brain barrier,
meninges [7] as well as in bone marrow-derived macro-
phages (BMMf) [8]. Only one cathelicidin encoding gene,
CAMP, has been found in humans [9]. This is highly
homologous to the single mouse cathelicidin gene, Camp
(also known as CnLp) [10]. Cathelicidins are synthesized as
precursors in a pre-pro-peptide form that is first cleaved into
a pro-peptide, designated pro-LL-37 or hCAP18 in humans
and pro-CRAMP (cathelin-related antimicrobial peptide) in
mice, and then to the mature bioactive peptide LL-37 or
CRAMP, respectively [11, 12]. Both LL-37 and CRAMP are
amphipathic,a-helical peptides, with a net positive charge of
(þ6) [10, 13] that preferentially binds to negatively charged
groups of the outer leaflet of the bacterial envelope. This
leads to displacement of lipids, alteration of membrane
structure and to the creation of a physical pore in the
membrane causing bacterial contents to leak out [14].
Cathelicidin expression is differentially regulated by
distinct pathogens upon infection. Whereas some micro-
organisms such as Shigella flexneri andVibrio cholerae inhibit
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cathelicidin production [15, 16], others like Group A
Streptococcus [4], Salmonella typhimurium [8], and Neisseria
meningitidis [7], upregulate its expression. This points to an
important role of cathelicidin in immunity, which was
confirmed by the use of Camp-deficient mouse models.
CRAMP-KO mice have impaired immunity to Group A
Streptococcus, with larger and persistent skin infections [17],
and are more susceptible to uropathogenic Escherichia coli
and meningococcal infection than wild-type mice [5, 7]. In
addition to its direct antimicrobial activity, cathelicidins
were suggested to act as multifunctional mediators that
modify the local inflammatory response and activate
adaptive immunity [18–20].
Pathogenic mycobacteria cause several long-term infec-
tions in their hosts with variable outcomes depending on the
virulence of the bacteria as well on the host’s immune
condition [21, 22]. Mice have been used to model such
infections and dissect protective mechanisms, namely the
effector molecules of mycobacterial control or killing. There
is little information about the immunological role of AMPs,
namely cathelicidin, during mycobacterial infections. We
recently showed that in vitro and in vivo killing of a
mycobacterial saprophyte involves cathelicidin-dependent
mechanisms [23]. In axenic conditions, killing of virulent
Mycobacterium tuberculosis can also be induced by treatment
with AMPs. Finally, cathelicidin-dependent killing was
shown to be important in M. tuberculosis killing in human
monocytes, by a mechanism dependent on TLR2/1 and
on the vitamin D pathway [24, 25]. Here we used
Mycobacterium avium, a mycobacterial species that is
pathogenic for mice, to address the role of cathelicidin in
the control of infection. Like other pathogenic mycobacteria,
M. avium resides primarily within macrophages, which
function both as the primary defensive host cell and the main
site of bacterial replication [21]. M. avium, unlike other
mycobacteria, is highly resistant to the classical killing
mechanisms that involve oxidative damage andmay be useful
in identifying additional killingmechanisms inmacrophages.
We show here thatM. avium induces rapid upregulation of
the CRAMP-encoding gene, in a TLR2- and TNF-dependent
manner, and that CRAMP production is not required for the
control ofM. avium growth in in vitro culturedmacrophages.
In vivo, CRAMP-deficientmice exhibited improved clearance
of the infection and presented an exacerbated immune
inflammatory response, as compared to wild-type animals.
Results
M. avium infection leads to upregulation of
cathelicidin expression
Pathogens modulate cathelicidin expression in different
ways, either by negative or positive regulation. To determine
in which way infection of murine macrophages with
M. avium regulates the expression of the CRAMP-encoding
gene, bone marrow macrophages (BMMf) isolated from
C57BL/6 mice were infected and the levels of Camp mRNA
were assessed by quantitative RT-PCR (qPCR). Infection was
shown to quickly induce upregulation of cathelicidin
expression, starting at 4 h post-infection, with a maximum
level of 60-fold increase 24 h after M. avium contact
(Fig. 1A).
M. avium-induced cathelicidin expression is
dependent on TLR2 and TNF
In order to determine cellular mechanisms involved in the
induction ofCamp upon infection withM. avium in BMMf,
we started by analysing if TLR2 is involved, given that this
bacterium acts as a TLR2 agonist [21]. Activation of BMMf
with the TLR2/6 agonist FSL-1 resulted in upregulation of
the CRAMP-encoding gene in a similar way to infection with
M. avium (Fig. 1B), suggesting that mycobacterial infection
might induce Camp expression in a TLR2-dependent
manner. To test this, BMMf from TLR2-deficient mice
were then infected with M. avium and Camp mRNA levels
were compared by qPCR to those observed in cells from
wild-type C57BL/6 animals. As shown in Figure 1C,
cathelicidin expression was strongly impaired in TLR2-
null macrophages, demonstrating that the induction of
CampmRNA upon infection withM. avium depends on the
activation of TLR2.
One important player in the control of mycobacterial
infections by macrophages is TNF production [26, 27],
and this cytokine strongly induces cathelicidin expression
in BMMf (Fig. S1). Given that TNF production by activated
macrophages is partially TLR2-dependent [28], we next
tested the ability of TNF-deficient BMMf to express
cathelicidin upon infection with M. avium or TLR2
activation. Mouse macrophages that do not produce TNF
have impaired Camp mRNA production upon infection or
activation of TLR2, when compared to wild-type cells
(Fig. 1D). This suggests that macrophage TNF production
upon stimulation of TLR2 by M. avium is important to
induce upregulation of cathelicidin. Together, these results
indicate that M. avium induces expression of the CRAMP-
coding gene, in BMMf, via activation of the TLR2 pathway
and production of TNF.
Upregulation of cathelicidin is not required for
the control of M. avium growth in mouse
macrophages
We next investigated the role of endogenous CRAMP in the
control of infection by M. avium, using wild-type and
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CRAMP-deficient BMMf. Given that available CRAMP-KO
mice were on a 129/SvJ background, we first determined by
qPCR the levels of cathelicidin expression in BMMf upon
infection with M. avium. In cells from this mouse strain
infection was also shown to induce upregulation of the
CRAMP-coding gene, but differed from C57BL/6 cells by
having higher levels at 48 h post-infection (Fig. 2A).
Treatment with FSL-1 led to a similar induction of Camp
expression, also suggesting that its induction byM. avium is
TLR2-dependent (Fig. 2B). Moreover, activation of murine
macrophages with TNF induced high cathelicidin expres-
sion, as shown in Figure 2B. We were also able to show here
that M. avium-infected BMMf produce cathelicidin at the
protein level, as seen by the presence of both pro- and
mature-CRAMP (18 and 5 kDa, respectively) by Western
blot analysis (Fig. 2C).
Treatment of BMMf with TNF or FSL-1 was previously
shown to restrict M. avium growth [27, 28] and we
demonstrate here that these stimuli induce the upregulation
of the CRAMP-encoding gene. Therefore, to address the
significance of cathelicidin synthesis and upregulation by
BMMf, we measured the intramacrophagic growth of M.
avium within wild-type and CRAMP-deficient macrophages
to evaluate whether CRAMP mediated the TNF- and FSL-1-
induced mycobacteriostasis. BMMf from 129/SvJ and
CRAMP-deficient mice were infected with M. avium at a
multiplicity of infection of two bacteria per macrophage, for
4 h. Infected cells were treated daily with TNF until day 4 post-
infection, or with a single dose of FSL-1 just after infection,
and the mycobacterial growth was then measured at different
time-points for up to 7 days, by counting CFUs. Both TNF
treatment and TLR2 activation with FSL-1 decreased the
observed increase inM. avium burden (Fig. 3). Wild-type and
CRAMP-deficient BMMf responded in a similar way and, as
depicted in Figure 3, the mycobacterial load at day 7 was not
affected by the lack of CRAMP production.
Figure 1. Expression of the CRAMP-coding gene in BMMf is altered by TLR2 and TNF stimulation, afterM. avium infection. Levels of CampmRNA were
determined by qPCR in cells derived from C57BL/6 mice, at different time points after infection withM. avium 2447 (A) or 24 h upon bacterial infection or
0.001mg/mL FSL-1 stimulation (B).Camp expression afterM. avium infection is impaired in cells derived from TLR2- (C) or TNF-deﬁcient mice (D). Induction
of Camp expression upon TLR2 stimulation with 0.001mg/mL FSL-1 is ablated in BMMf derived from TNF-deﬁcient mice (D). Values represent the mean
fold expression relative to non-infected or untreated control cells, obtained from triplicate cultures from one representative experiment.
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These results show that the absence of the antimicrobial
peptide CRAMPdoes not affect the permissiveness of BMMf
to M. avium growth, and that macrophages can inhibit
intracellular mycobacterial growth upon cytokine treatment
even when they are unable to produce cathelicidin.
Cathelicidin-derived peptides exhibit
bacteriostatic activity towards axenically
grown M. avium
To investigate if M. avium is susceptible to the antimicrobial
peptide cathelicidin, the bacterium was grown in vitro in 7H9
broth in the presence of increasing concentrations of a CRAMP
analogue. As shown in Figure 4, the peptide restricted in a dose-
relatedmanner the growth ofM. aviumwith a concentration of
58.81 0.07mM leading to a 50% reduction in growth
(means SEM from four independent experiments).
Role of CRAMP in the control of in vivo infections
with M. avium
We next investigated the in vivo role of murine cathelicidin
in M. avium infection. CRAMP-deficient mice were
Figure 3. Comparison between the intracellular growth of M. avium
2,447 inside BMMf from 129/SvJ or CRAMP-KO mice, for 7 days.
Macrophages were infected with 106 CFU per well and were either left
untreated or were treated with TNF (50U/mL) or FSL-1 (0.001mg/mL). The
difference of log10 CFU per well between days 0 and 7 post-infection was
designated log10 increase CFU. The results shown are the mean log10
increase CFU per well 1 SD from three wells for each condition. One
representative experiment is depicted from a total of three experiments.
Statistics is relative to untreated BMMf from the same genetic
background.
Figure 2. Expression of the CRAMP-coding gene in BMMf derived from 129/SvJ mice. Cells were infected with M. avium 2447 and the levels of Camp
mRNAwere determined at different time points (A). Camp expressionwas quantiﬁed 48 h after 50U/mL TNF or 0.001mg/mL FSL-1 stimulation or bacterial
infection (B). Values were determined by qPCR and represent themean fold expression relative to non-infected or untreated control cells. Detection of the
CRAMP peptide in BMMf (C). Protein extracts (30mg) from Camp-expressing (lanes a and b) or Camp-deﬁcient (lane c) macrophages were analysed by
Western blot using a CRAMP(1-39) antibody. Cells were either left non-infected (a) or infected with M. avium 2,447 (b, c). Data were obtained from
triplicate cultures from one representative experiment out of a total of three experiments.
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intravenously infected with 106 CFU of M. avium (strains
2,447 (intermediate virulence) or 25,291 (high virulence))
and the mycobacterial infection was followed in the liver and
spleen for up to 180 days and compared to that in 129/SvJ
control animals. M. avium 2,447 was shown to be slowly
eliminated from the livers of both CRAMP-deficient and
wild-type mice at similar rates in both strains (Fig. 5A). In
the spleen, after an initial 60-day period of proliferation, the
growth of this bacterial strain was arrested. Such control of
infection was slightly and transiently improved in the spleen
of CRAMP-deficient mice as compared to control animals.
Spleen cells from CRAMP-deficient mice responded to
mycobacterial antigens with superior IFNg production as
compared to cells from control animals (Fig. 5B). CRAMP-
deficient mice had a greater expansion of splenic CD4þ T
cells at late time-points of infection when compared to
control animals (Fig. 5C) and also showed increased
numbers of B cells, myeloid CD11bþ cells and regulatory
(CD4þCD25þFoxP3þ) T cells.
Similar data were obtained for the highly virulent strain
25,291 showing an improved splenic control of the infection
(Fig. 6A) and enhanced expansion of lymphocytes (Fig. 6B)
in CRAMP-deficient mice as compared to control animals.
Discussion
We started by analysing the expression of the cathelicidin-
coding gene inmurinemacrophages infected withM. avium.
Infection of BMMf, TLR2/6 activation or treatment with
TNF, all led to an increase of CampmRNA levels. In order to
get insights into the mechanism by whichM. avium induces
cathelicidin expression, we showed that TLR2 or TNF
knockdown strongly impaired M. avium-induced Camp
expression. Additionally, in FSL-1 stimulated TNF-null
BMMf, cathelicidin expression is highly reduced when
compared to wild-type cells. Given that M. avium is a TLR2
agonist [28] and that Camp mRNA expression upon
bacterial infection depends on TLR2 activation, our data
suggest that TNF production after TLR2 stimulation by M.
avium is crucial to induce murine cathelicidin expression.
TLR2 stimulation leads to the recruitment of a series of
adaptor molecules that lead to the activation of NF-kB [29].
Previous findings showed that the promoter of the mouse
cathelicidin-coding gene contains predicted binding sites for
this transcription factor [11], and more recently NF-kB was
shown to induce CRAMP expression in murine mast
cells [30]. Although we did not address the role of NF-kB
on M. avium-induced transcription of Camp, it is probable
that this transcription factor mediates the effect of TLR2
activation on Camp expression. It should be noted that there
is no NF-kB response element in the human cathelicidin-
encoding gene [31], but rather multiple vitamin D receptor
elements (VDREs) that are not found in the murine
counterpart [32]. This is consistent with the observed
absence of CRAMP induction by the active form of vitamin
D3 in mouse cells [33] and also with the fact that mice, as
nocturnal animals, evolved in such a way as to not respond to
vitamin D3 synthesis upon solar exposure. These observa-
tions point to clear differences in the regulation of the
human and mouse cathelicidin-encoding genes. However,
TLR2 triggering in human cells may still lead to activation of
cathelicidin expression via TNF induction, something which
is worth looking at. In our experiments, TNF is only partly
responsible for the transcription of the gene possibly because
TLR2 signalling is acting directly as well. TNF can be seen as
an autocrine or paracrine enhancer of such expression. This
may differ in human cells. We also observed residual
induction of cathelicidin expression in the absence of TLR2
suggesting that other receptors in macrophages, possibly
signalling via NF-kB, may have a minor role in promoting
the expression of this gene.
We also show here that the cathelicidin-related antimi-
crobial peptide is not required for the control of M. avium
growth in mouse macrophages despite the observation that
its expression is effectively induced upon contact with
mycobacteria or bacteriostasis-inducing cytokines or TLR2-
agonists. These data might be consistent with an endogenous
resistance of this mycobacterial species to this antimicrobial
molecule. However, we found that an analogue of LL-37, the
human version of this peptide, is active against M. avium
2,447 (Fig. 4). This raises the possibility that endogenous
CRAMP may not reach the compartment inhabited by the
mycobacterium. Future work will address whether the
intracellular targeting of the mycobacteria by the peptide is
the basis of the present observations or whether infection
Figure 4. Dose–response curve of the inhibition of M. avium growth vs.
peptide concentration. The IC50 values were calculated from the
represented curve, as the concentration needed to inhibit by 50% the
mycobacterial growth. The mean SEM for each concentration is
represented considering the results obtained in triplicates for four
independent experiments.
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modulates peptide production at post-transcriptional levels.
These in vitro data were corroborated by the in vivo infection
experiments that showed that CRAMP-deficient mice were
not more susceptible to infection. Unexpectedly, however, a
slight improvement of bacterial control was observed in the
spleen of CRAMP-deficient mice as compared to wild-type
controls. This was paralleled by an exacerbation of the
inflammatory responses in the former animals as compared
to the latter. Thus, we detected an increased IFN-g response,
an augmented CD4þ T cell expansion and an increased
accumulation of different populations of leukocytes in the
spleen of CRAMP-deficient animals as compared to their
controls. We conclude that not only does CRAMP fail to act
as an effector antimicrobial mechanism againstM. avium in
mouse macrophages as it limits inflammation mediated by
the immune response.
Cathelicidin-derived peptides have already been shown to
have immunomodulatory activities (reviewed in [34]).
Cathelicidin peptides may act on phagocytic cells either
promoting [35] or reducing [36] their pro-inflammatory
activity, promoting Th1 responses [37]. Camp-deficient
mice had altered in vivo B and T cell responses to model
Figure 5. Characterisation of the infection and immune response following an intravenous challenge of 129/SvJ and CRAMP-KO mice with M. avium
2,447. Bacterial growth in the spleen and liver of control 129/SvJ and CRAMP-KO animals (A). IFN-g secreted by spleen cells from 129/SvJ or CRAMP-KO
mice infected withM. avium 2,447, after in vitro stimulation for 72 hwithM. avium antigens (B). Supernatants were collected and IFN-gwas quantiﬁed by
ELISA. Number of splenic cells expressing CD4, CD8, CD19, CD11b or CD4CD25Foxp3 in the different time points of infection (C), as analysed by ﬂow
cytometry. Data are represented as the mean value SD from three to ﬁve animals per group, from one representative experiment out of a total of two
experiments.
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antigens [38]. Using an in vivomouse model of infection, we
showed here that the inhibitory effects of CRAMP dominate
over potentially adjuvant effects. We postulate that if we can
directionally target these peptides to phagosomes, catheli-
cidin-derived peptides may serve not only to help eliminate
the pathogen but to limit pathology associated with
mycobacterial disease. This will require proper encapsula-
tion in a delivery system that will reach phagosomes within
macrophages residing in granulomas.
Although we centred our in vitro studies on macrophages,
other cell types produce cathelicidin. Most prominently,
neutrophils are the richer source for these proteins/peptides,
Figure 6. Characterisation of the infection and immune response following an intravenous challenge of 129/SvJ and CRAMP-KO mice with M. avium
25,291. Bacterial growth in the spleen and liver of control 129/SvJ and CRAMP-KO animals (A). Number of splenic cells expressing CD4, CD8, CD19 or
CD11b in the different time points of infection (B), as analysed by ﬂow cytometry. Data are represented as the mean value SD from three to ﬁve animals
per group of one experiment.
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which are stored within their specific granules [39]. Though,
neutrophils are not the major phagocytes recruited to the
mycobacterial granuloma although they may be found
there and could donate their content to the infected
macrophage [40]. However, depletion of neutrophils or
neutrophil granule defects inmice cause an early exacerbation
of M. avium growth leading to a significant increase in
bacterial loads in the first days of infection which is
maintained in the ensuing weeks [41], something which
was not observed in the CRAMP-deficient mice. It is thus
unclear what the cellular source for cathelicidin is in our
model. An experimental model of aerogenic tuberculosis
infection identified macrophages, bronchial epithelial cells
and pneumocytes as the cellular sources or sites of
accumulation of most of the cathelicidin induced by
infection [42]. It is thus likely that many cells contribute,
although it still remains to be known which fraction or
fractions will play a role in infection.
Materials and methods
Mice and bacterial strains
129/SvJ mice were purchased from Charles River Laborato-
ries, Inc. (Barcelona, Spain), and C57BL/6 mice were bred in
our facilities. CRAMP-deficient (CRAMP-KO) mice, on a
129/SvJ background, were bred at the IBMC facilities from a
breeding pair provided by Dr. R. Gallo (University of
California, USA) [17]. TLR2-deficient mice, on a C57BL/6
background, were bred in our facilities from a breeding pair
kindly provided by Drs. O. Takeuchi and S. Akira from the
Research Institute for Microbial Diseases (Osaka University,
Japan). TNF-deficient mice, on a C57BL/6 background, were
purchased from B&KUniversal and bred in our facilities. All
mice were kept at the IBMC animal facilities, in high
efficiency particulate air (HEPA)-filter-bearing cages under
12 h light cycles, and were given sterile chow and autoclaved
water ad libitum. All animal experiments were performed in
accordance with national and European guidelines for the
care and handling of laboratory animals and have been
approved by the National Veterinary Board.
The highly virulent M. avium strain 25,291, forming
smooth transparent (SmT) colonies, was obtained from the
American Type Culture Collection (Manassas, VA, USA).
Strain 2,447 SmT (isolated from an AIDS patient) was
provided by Dr. F. Portaels (Institute of Tropical Medicine,
Antwerp, Belgium). M. avium strain 2,447 SmT was used
unless indicated otherwise in the text. Bacteria inocula were
prepared as previously described [28].
Infection of mice and study of immune cells
Female 129/SvJ and CRAMP-deficient mice aged 8–14 weeks
were infected intravenously with 106 CFUs of M. avium
strains 2,447 or 25,291 through a lateral tail vein. At different
time points, animals (n¼ 3–5) were anesthetised with
isoflurane and retro-orbital bleeding was performed before
sacrifice, also with isoflurane. The livers and spleens were
removed in aseptic conditions, homogenised, and serially
diluted in distilled sterile water containing 0.05% Tween 80.
The resulting suspensions were plated into Middlebrook
7H10 agar medium (BD-Difco, Sparks, MD, USA) supple-
mented with 10% OADC (oleic acid-albumin-dextrose-
catalase) and the number of CFUs counted after 7–9 days of
incubation at 37 8C.
Single-cell suspensions from spleens were prepared by
teasing portions of the spleen with two sterile slides in
DMEM supplemented with 10% FBS. Cells were pelleted by
centrifugation, washed with HBSS (Gibco Invitrogen,
Paisley, UK), and erythrocytes were lysed with an NH4Cl
hemolytic buffer. Cell suspension was then washed with
HBSS, resuspended in DMEM with 10% FBS, and used for
population analysis by flow cytometry or for in vitro
stimulation studies. Splenic cells were cultivated at a density
of 2 105 cells/well in a U-bottom, 96-well cell culture plate
and incubated in triplicate in DMEM with 10% FBS, 2mM
L-glutamine (Gibco Invitrogen), 10mM HEPES (Gibco
Invitrogen), 1mM sodium pyruvate (Gibco Invitrogen),
100U/mL penicillin 100mg/mL streptomycin (Gibco In-
vitrogen), with no further stimulus or in the presence of
mycobacterial envelope proteins or Con A (Sigma), both at a
concentration of 4mg/mL. Supernatants from the cultures
were collected after 72 h of incubation at 37 8C in a 7% CO2
atmosphere, and the IFN-g produced was quantified by a
two-site sandwich ELISA method, using anti-mouse IFN-g
specific antibodies (R4-6A2, BD Pharmingen, San Jose,
California, USA, as capture and biotinylated AN-18 as
detecting antibody). A standard curve was generated with
known amounts of recombinant murine IFN-g (Genzyme).
Mycobacterial envelope proteins were prepared from
M. avium broth cultures as previously described [43].
Flow cytometry
For the immunofluorescence staining, 106 splenic cells were
incubated in a 96-well plate, for 30min at 4 8C and in the
dark, with FITC-conjugated anti-mouse CD4 (diluted
1:400) and PE-conjugated anti-mouse CD8 (diluted
1:400) antibodies, or with FITC-conjugated anti-mouse
CD19 (diluted 1:400) and PE-conjugated anti-mouse
CD11b (diluted 1:400) antibodies, in PBS containing 1%
FBS. All antibodies were from Biolegend (San Diego, CA,
USA). The cells were washed twice with PBS containing 1%
FBS, and the analysis of the cell population was based on the
acquisition of 20,000 events in a FACSCalibur flow
cytometer (BD Biosciences) equipped with CellQuest and
FlowJo softwares.
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For the analysis of Foxp3 intracellular expression, cells
were first stained for the surface molecules, with FITC-
conjugated anti-mouse CD4 (diluted 1:400) and PE-
conjugated anti-mouse CD25 (diluted 1:400) antibodies
(Biolegend), and after fixation and permeablisation, were
incubated with an Alexa Fluor 647 conjugated anti-mouse
Foxp3 (eBiosciences) based on the manufacturer’s
recommendations.
Cell culture
BMMf were obtained by culturing the bone marrow cells
that were flushed from the femurs of male mice with cold
HBSS. The resulting cell suspension was centrifuged and the
cells gently resuspended in DMEM supplemented with
10mM L-glutamine, 10mM HEPES, 1mM sodium pyru-
vate, 10% FBS, and 10% L929 cell-conditioned medium
(LCCM) as source ofM-CSF. To remove fibroblasts, the cells
were cultured overnight, at 37 8C in a 7% CO2 atmosphere,
on cell culture dishes. The non-adherent cells were collected
with HBSS, distributed in 24-well plates (5 105 cells/well)
and incubated at 37 8C in a 7% CO2 atmosphere. After
3 days, 10% LCCM was added. On day 7, the medium was
renewed with warm DMEM containing 10% FBS and 10%
LCCM. On day 10, the cells were fully differentiated into
macrophages. For the quantitative analysis of Camp mRNA
expression in BMMf and preparation of whole cell extracts,
cells were distributed in 6-well plates (2 106 cells/well).
Infection and treatments of BMMf
On the 10th day of culture, about 106M. avium (2 bacteria
per macrophage) was added to each well containing the
macrophages, in 0.2mL DMEM. After 4 h of incubation at
37 8C in a 7% CO2 atmosphere, cells were washed four times
with warm HBSS to remove non-internalised mycobacteria
and re-incubated in DMEM with 10% FBS and 10% LCCM.
To quantify the number of intracellular mycobacteria,
macrophages from triplicate wells were immediately lysed
(time zero of infection) with 0.1% saponin (Sigma), and the
number of viable bacteria counted as described below.
The other cells were incubated for 7 days to measure the
intracellular growth of the bacteria. Some macrophages were
treated daily with recombinant murine TNF (50U/mL/day,
Peprotech EC, London, UK), during the first 4 days of
infection, or treated with fibroblast-stimulating lipopeptide-
1 (FSL-1, 0.001mg/mL, EMC Microcollections, Tbingen,
Germany) just after infection. The measurement of
mycobacterial growth was done by counting CFUs. Briefly,
the cells were lysed by adding 0.1% saponin to each well, the
resulting bacterial suspension was 10-fold serially diluted in
water containing 0.05% Tween 80, and the dilutions were
plated into Middlebrook 7H10 agar plates. The number of
colonies was counted after 7–9 days of incubation at 37 8C.
For each condition tested, three culture wells were used.
Isolation of RNA from BMMf and quantitative
RT-PCR analysis for Camp
For the quantitative analysis of Camp mRNA expression in
BMMf, triplicates were harvested after infection with M.
avium (mycobacteria added in 0.8mL DMEM) or after
treatment with a single dose of either TNF (50U/mL) or
FSL-1 (0.001mg/mL). Total RNA was extracted from
macrophages using the PureLinkTM Micro-to-Midi Total
RNA Purification System (Gibco Invitrogen), according to
the manufacturer’s instructions. Quality of RNA was
assessed by determining the OD260/280 ratio and by
visualisation following agarose gel electrophoresis and
ethidium bromide stain. Up to 1mg of total RNA was
transcribed into cDNA, using the RevertAidTM H Minus
First Strand cDNA Synthesis kit (Fermentas) according to
the recommendation of the manufacturer, with an oligo(-
dT)18 primer. To quantify the gene expression, cDNA for
hypoxanthine phosphoribosyltransferase (HPRT) (house-
keeping) and CRAMP was amplified using the following
primers: HPRT: 50-GTAATGATCAGTCAACGGGGGAC-30
(forward) and 50-CCAGCAAGCTTGCAACCTTAACCA-30
(reverse); CRAMP: 50-AAGGAA-CAGGGGGTGGTG-30
(forward) and 50-CCGGGAAATTTTCTTGAACC-30 (re-
verse). The primers were shown not to co-amplify genomic
DNA. A standard curve was generated for each primer pair
by using five fourfold dilutions of cDNA from BMMf, to
ensure that PCR efficiency was near 100% and within 5% of
each other. All reactions were performed in a total reaction
volume of 20mL, with iQTM SYBRR Green Supermix (Bio-
Rad Laboratories), and carried out in a iQTM 5 instrument
(Bio-Rad Laboratories) with the following parameters:
HPRT - 95 8C for 30 s, followed by 40 cycles (91 8C for
10 s, 59 8C for 25 s and 72 8C for 25 s); CRAMP – 92 8C for
30 s, followed by 40 cycles (91 8C for 10 s and 65 8C for 25 s).
For each primer pair, a negative control (water) was included
during cDNA quantification. After PCR amplification, a
melting curve was generated for every PCR product to check
the specificity of the PCR reaction. Baseline thresholds were
calculated by the Bio-Rad iQ5 program and the threshold
cycles (CT) were used in the Livak (2
44CT ) method [44],
where CT values for CRAMP were normalized to expression
levels of HPRT. Data are reported as n-fold changes relative
to the control samples.
Preparation of whole cell extracts and
immunoblot analysis
For the isolation of protein from BMMf, cells were washed
twice with ice-cold PBS and lysed with ice-cold RIPA buffer
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(50mM Tris–HCl pH 8.0, 150mM sodium chloride, 1%
Igepal, 0.5% sodium deoxycholate, 0.1% SDS, 1mM EDTA)
containing 1:100 protease inhibitors (Sigma) at 4 8C.
Adherent cells were scrapped and the cell extracts were
centrifuged to remove cell debris. Total proteins were
precipitated with trichloroacetic acid and resuspended in
electrophoresis sample buffer (50mM Tris–HCl pH 8.8, 2%
SDS, 0.017% bromophenol blue, 10% glycerol, 2mMEDTA,
100mMDTT). Equal amounts of protein (30mg), as defined
using the Micro BCA Protein Assay (Pierce) were loaded
onto a 12% SDS–PAGE gel, subjected to electrophoresis and
transferred to a 0.45mm nitrocellulose membrane (Amer-
sham Biosciences, Piscataway, NJ, USA) by application of
100V for 60min at 4 8C. The membrane was blocked in 5%
fat-free milk in PBS-0.1% Tween (PBST) for 1 h at room
temperature, and then incubated overnight with a polyclonal
rabbit anti-CRAMP(1-39) antibody (Innovagen) diluted
1:500 in PBST with 5% fat-free milk, at 4 8C. Incubation
with the secondary antibody, a horseradish peroxidase-
conjugated sheep anti-rabbit IgG (The Binding Site,
Birmingham, UK) diluted 1:10,000 in PBST with 5% fat-
free milk, was performed for 45min at room temperature.
Immunoreactivity was visualized using an enhanced chemi-
luminescence (ECL) reagent (Pierce) according to the
manufacturer’s instructions.
Determination of LLKKK18 effect on the growth
of M. avium
Frozen aliquots of M. avium strain 2,447 were thawed and
diluted to a final concentration of 106 CFU/mL in
Middlebrook 7H9 broth medium supplemented with 10%
ADC and 0.05% Tween 80. After 2 days (lag phase), the
density of a 1:2 dilution of the axenic culture was measured
daily at 600 nm until it reached an OD of about 0.132,
corresponding to a 0.5 McFarland standard. At this point,
the axenic culture was diluted 1:10 in 7H9 broth medium to
attain a concentration of 107 CFU/mL and the assay was
initiated by adding M. avium to a 96-well plate.
The mycobactericidal effect of LLKKK18 (KEFKRIVK-
RIKKFLRKLV), an analogue of the cathelicidin LL37, was
determined by adding serial dilutions (between 3.13 and
100mM) of this peptide to the axenic culture. The
microplate was then incubated in a humidified chamber at
37 8C and the ODmeasured daily at 600 nm, for up to 7 days.
The inhibition ofM. avium growth at day 7 was expressed as
a percentage, towards a control of M. avium grown in the
absence of LLKKK18, and the concentration needed to
reducemycobacterial growth by 50% (IC50) was determined.
All measurements were performed in triplicate. Viable
mycobacteria at day 7 were also quantified by plating serial
dilutions of the suspensions on solid Middlebrook 7H10
agar medium supplemented with 10% OADC. Colony-
forming units (CFUs) in each plate were counted 7 days after
plating.
Statistical analysis
Statistically significant differences between groups were
determined using the Student’s t-test (two-tailed, equal
variances). Significance was referred like  for P< 0.05 and
like  for P< 0.01.
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Figure S1. Expression of the CRAMP-coding gene in BMMf
from C57BL/6 mice, upon TNF stimulation. After a 4 h
treatment with 50U/mL TNF, cells were washed and the
levels of Camp mRNA were determined by qPCR at the
different time points indicated in the graph. Values represent
the mean fold expression relative to non-infected or
untreated control cells, obtained from triplicate cultures
from one representative experiment.
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